Neuro-Oncology

Article	Citations
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary	4362
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013–2017	1119
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014–2018	756
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions	518
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015–2019	364
EANO guideline on the diagnosis and management of meningiomas	224
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter	155
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial	136
Epidemiology of brain metastases and leptomeningeal disease	118
EIF4A3-induced circular RNA ASAP1 promotes tumorigenesis and temozolomide resistance of glioblastoma via NRAS/MEK1/ERK1–2 signaling	110
Fully automated hybrid approach to predict theIDHmutation status of gliomas via deep learning and radiomics	110
The 2021 WHO Classification of Tumors of the Central Nervous System: clinical implications	104
Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas	102
Phase I/II study of tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma	98
The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis	89
CBTRUS Statistical Report: Pediatric Brain Tumor Foundation Childhood and Adolescent Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014–2018	82
Associations of meningioma molecular subgroup and tumor recurrence	78
Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial	77
Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group	75
Modeling glioblastoma invasion using human brain organoids and single-cell transcriptomics	73
A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR	73
Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial	72
Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia in glioblastoma patients: phase II randomized study of protons vs photons	72
IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification	72
Cancer cell heterogeneity and plasticity: A paradigm shift in glioblastoma	71

A molecularly integrated grade for meningioma	70
A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study	65
Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors	65
Ferroptosis, as the most enriched programmed cell death process in glioma, induces immunosuppression and immunotherapy resistance	63
Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG)	63
Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)	62
SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors	62
A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)	61
Cell-surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery	60
Neuro-oncology management during the COVID-19 pandemic with a focus on WHO grades III and IV gliomas	60
EANO, SNO and Euracan consensus review on the current management and future development of intracranial germ cell tumors in adolescents and young adults	60
Increased activation of HDAC1/2/6 and Sp1 underlies therapeutic resistance and tumor growth in glioblastoma	59
Association of supratotal resection with progression-free survival, malignant transformation, and overall survival in lower-grade gliomas	58
Brain metastasis detection using machine learning: a systematic review and meta-analysis	58
Rolling-translated EGFR variants sustain EGFR signaling and promote glioblastoma tumorigenicity	58
Unique challenges for glioblastoma immunotherapy—discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank	57
Genome-wide methylation profiling of glioblastoma cell-derived extracellular vesicle DNA allows tumor classification	57
PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma	57
Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors	56
MR-guided focused ultrasound liquid biopsy enriches circulating biomarkers in patients with brain tumors	56
Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein	56
Clinical trial of proton craniospinal irradiation for leptomeningeal metastases	55
CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design	54
Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study	54
Artificial intelligence neuropathologist for glioma classification using deep learning on hematoxylin and eosin stained slide images and molecular markers	53
A serum-based DNA methylation assay provides accurate detection of glioma	53
Excellent outcome of young children with nodular desmoplastic medulloblastoma treated on “Head Start” III: a multi-institutional, prospective clinical trial	52
The evolution of the cancer stem cell state in glioblastoma: emerging insights into the next generation of functional interactions	52
Immune effector cell–associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes	50
Treatment of an aggressive orthotopic murine glioblastoma model with combination checkpoint blockade and a multivalent neoantigen vaccine	49
MR imaging features of diffuse intrinsic pontine glioma and relationship to overall survival: report from the International DIPG Registry	49
TGF-β1 modulates temozolomide resistance in glioblastoma via altered microRNA processing and elevated MGMT	49
Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group	48
MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence	48
Urgent considerations for the neuro-oncologic treatment of patients with gliomas during the COVID-19 pandemic	48
Neoplastic and immune single-cell transcriptomics define subgroup-specific intra-tumoral heterogeneity of childhood medulloblastoma	47
A prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastoma	46
Synaptic input to brain tumors: clinical implications	46
Phase I study of intraventricular infusions of autologous ex vivo expanded NK cells in children with recurrent medulloblastoma and ependymoma	44
A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1–associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trial	44
A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenib	43
Loss of H3K27me3 in meningiomas	43
Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q	43
Deregulated expression of the imprinted DLK1-DIO3 region in glioblastoma stemlike cells: tumor suppressor role of lncRNA MEG3	42
Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naïve diffuse midline glioma models	41
Proton and carbon ion radiotherapy in skull base chordomas: a prospective study based on a dual particle and a patient-customized treatment strategy	41
Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: An open-label, multi-institutional phase I trial	41
Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions	41
A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylatedMGMTglioblastoma: the VERTU study	40
Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas	40

Extensive peritumoral edema and brain-to-tumor interface MRI features enable prediction of brain invasion in meningioma: development and validation	39
Pharmacologic inhibition of lysine-specific demethylase 1 as a therapeutic and immune-sensitization strategy in pediatric high-grade glioma	39
Clinical, molecular, and radiomic profile of gliomas with FGFR3-TACC3 fusions	38
Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review	38
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)	37
Impact of the methylation classifier and ancillary methods on CNS tumor diagnostics	37
TGF-β promotes microtube formation in glioblastoma through thrombospondin 1	36
Hippocampal radiotherapy dose constraints for predicting long-term neurocognitive outcomes: mature data from a prospective trial in young patients with brain tumors	36
European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)	36
Clinical features, neurologic recovery, and risk factors of postoperative posterior fossa syndrome and delayed recovery: a prospective study	35
Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas	35
Liquid biopsy in gliomas: A RANO review and proposals for clinical applications	35
Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results	35
Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy	35
Functional connectivity within glioblastoma impacts overall survival	35
Longitudinal evaluation of peripheral nerve sheath tumors in neurofibromatosis type 1: growth analysis of plexiform neurofibromas and distinct nodular lesions	35
Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions	34
Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma	34
Brain exposure of the ATM inhibitor AZD1390 in humans—a positron emission tomography study	34
MGMTpromoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review	33
Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma	33
Cisplatin-induced peripheral neuropathy is associated with neuronal senescence-like response	33
An international multicenter matched cohort analysis of incidental meningioma progression during active surveillance or after stereotactic radiosurgery: the IMPASSE study	33
Establishment of patient-derived organoid models of lower-grade glioma	33
Histiocytosis and the nervous system: from diagnosis to targeted therapies	32
Off-the-shelf, steroid-resistant, IL13Rα2-specific CAR T cells for treatment of glioblastoma	32
Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma	32
Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial	32
The Japan Society for Neuro-Oncology guideline on the diagnosis and treatment of central nervous system germ cell tumors	32
The PI3K/Akt/mTOR pathway as a preventive target in melanoma brain metastasis	32
Combined molecular subtyping, grading, and segmentation of glioma using multi-task deep learning	32
Identification of diverse tumor endothelial cell populations in malignant glioma	31
Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas	31
DNA methylation profiling as a model for discovery and precision diagnostics in neuro-oncology	31
Next-generation sequencing of cerebrospinal fluid for clinical molecular diagnostics in pediatric, adolescent and young adult brain tumor patients	31
H3K27me3 loss indicates an increased risk of recurrence in the Tübingen meningioma cohort	31
Crosstalk between GBM cells and mesenchymal stemlike cells promotes the invasiveness of GBM through the C5a/p38/ZEB1 axis	31
AI-based prognostic imaging biomarkers for precision neuro-oncology: the ReSPOND consortium	31
Hippocampal avoidance whole-brain radiotherapy without memantine in preserving neurocognitive function for brain metastases: a phase II blinded randomized trial	31
MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus	30
Blood exosomes-based targeted delivery of cPLA2 siRNA and metformin to modulate glioblastoma energy metabolism for tailoring personalized therapy	30
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016—2020	29
PTRF/cavin-1 remodels phospholipid metabolism to promote tumor proliferation and suppress immune responses in glioblastoma by stabilizing cPLA2	29
Phase II trial of hippocampal-sparing whole brain irradiation with simultaneous integrated boost for metastatic cancer	29
Mechanisms of imipridones in targeting mitochondrial metabolism in cancer cells	29
MEF2C silencing downregulates NF2 and E-cadherin and enhances Erastin-induced ferroptosis in meningioma	29
The impact of socioeconomic status (SES) on cognitive outcomes following radiotherapy for pediatric brain tumors: a prospective, longitudinal trial	29
DNA methylation based glioblastoma subclassification is related to tumoral T-cell infiltration and patient survival	29
Anti-invasive efficacy and survival benefit of the YAP-TEAD inhibitor verteporfin in preclinical glioblastoma models	28
Phase II trial of response-based radiation therapy for patients with localized germinoma: a Children’s Oncology Group study	28
Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse	28
A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma	28
The natural history of vestibular schwannoma growth—prospective 40-year data from an unselected national cohort	28
Single-cell transcriptome and genome analyses of pituitary neuroendocrine tumors	27
Management of neurofibromatosis type 1-associated plexiform neurofibromas	27
Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of ivosidenib	27
Immunotherapy in association with stereotactic radiotherapy for non-small cell lung cancer brain metastases: results from a multicentric retrospective study on behalf of AIRO	27
A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid phar	27
Epidemiology of brainstem high-grade gliomas in children and adolescents in the United States, 2000-2017	27
Racial disparities in supportive medication use among older patients with brain metastases: a population-based analysis	26
TRIM24 promotes stemness and invasiveness of glioblastoma cells via activating Sox2 expression	26
Corrigendum to: CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013–2017	26
Newly established patient-derived organoid model of intracranial meningioma	26
Actinomycin D downregulates Sox2 and improves survival in preclinical models of recurrent glioblastoma	26
The genetic landscape of choroid plexus tumors in children and adults	26
The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies	26
The combined use of steroids and immune checkpoint inhibitors in brain metastasis patients: a systematic review and meta-analysis	26
Multiparametric MRI for early identification of therapeutic response in recurrent glioblastoma treated with immune checkpoint inhibitors	26
The use of external control data for predictions and futility interim analyses in clinical trials	26
Dual IGF1R/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant	25
Surgical resection of glioblastomas induces pleiotrophin-mediated self-renewal of glioblastoma stem cells in recurrent tumors	25
Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review	25
Glioblastoma genetic drivers dictate the function of tumor-associated macrophages/microglia and responses to CSF1R inhibition	25
Long-term metabolic evolution of brain metastases with suspected radiation necrosis following stereotactic radiosurgery: longitudinal assessment by F-DOPA PET	25
A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma	25
Role of CX3CR1 signaling in malignant transformation of gliomas	25
Importance of the intersection of age and sex to understand variation in incidence and survival for primary malignant gliomas	25
Phase I/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: A Children’s Oncology Group report	24
Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033-26033	24
TERT and DNMT1 expression predict sensitivity to decitabine in gliomas	24

Liquid biopsy detection of genomic alterations in pediatric brain tumors from cell-free DNA in peripheral blood, CSF, and urine	24
Rapid, label-free detection of diffuse glioma recurrence using intraoperative stimulated Raman histology and deep neural networks	24
Distinct metabolic hallmarks of WHO classified adult glioma subtypes	24
JAM-A functions as a female microglial tumor suppressor in glioblastoma	24
So-called bifocal tumors with diabetes insipidus and negative tumor markers: are they all germinoma?	24
EPEN-54. ACNS0831, PHASE III RANDOMIZED TRIAL OF POST-RADIATION CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED EPENDYMOMA AGES 1 TO 21 YEARS	24
Blood-brain barrier alterations in human brain tumors revealed by genome-wide transcriptomic profiling	23
Deep learning-based automatic tumor burden assessment of pediatric high-grade gliomas, medulloblastomas, and other leptomeningeal seeding tumors	23
Tumor cell network integration in glioma represents a stemness feature	23
EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection	23
IDH-mutated gliomas promote epileptogenesis through d-2-hydroxyglutarate-dependent mTOR hyperactivation	23
Randomized multi-reader evaluation of automated detection and segmentation of brain tumors in stereotactic radiosurgery with deep neural networks	23
Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States	23
Advancing biology-based therapeutic approaches for atypical teratoid rhabdoid tumors	23
Clinical impact of combined epigenetic and molecular analysis of pediatric low-grade gliomas	23
Cannabidiol converts NF-κB into a tumor suppressor in glioblastoma with defined antioxidative properties	23
NF1 optic pathway glioma: analyzing risk factors for visual outcome and indications to treat	22
Alpha 1-antichymotrypsin contributes to stem cell characteristics and enhances tumorigenicity of glioblastoma	22
Meclofenamate causes loss of cellular tethering and decoupling of functional networks in glioblastoma	22
Second series by the Italian Association of Pediatric Hematology and Oncology of children and adolescents with intracranial ependymoma: an integrated molecular and clinical characterization with a lon	22
Cognitive preservation following awake mapping-based neurosurgery for low-grade gliomas: A longitudinal, within-patient design study	22
PTEN deficiency leads to proteasome addiction: a novel vulnerability in glioblastoma	22
Population-based estimates of survival among elderly patients with brain metastases	21
Targeting radiation-tolerant persister cells as a strategy for inhibiting radioresistance and recurrence in glioblastoma	21
Prognostic relevance of clinical and molecular risk factors in children with high-risk medulloblastoma treated in the phase II trial PNET HR+5	21
The long noncoding RNA lnc-HLX-2-7 is oncogenic in Group 3 medulloblastomas	21
Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastoma	21
Improving the noninvasive classification of glioma genetic subtype with deep learning and diffusion-weighted imaging	21
Inhibition of SETMAR–H3K36me2–NHEJ repair axis in residual disease cells prevents glioblastoma recurrence	21
DNA methylation-based prognostic subtypes of chordoma tumors in tissue and plasma	21
LTBK-04. PHASE 2 MULTICENTER STUDY OF THE ONCOLYTIC ADENOVIRUS DNX-2401 (TASADENOTUREV) IN COMBINATION WITH PEMBROLIZUMAB FOR RECURRENT GLIOBLASTOMA; CAPTIVE STUDY (KEYNOTE-192)	21
Sexually dimorphic radiogenomic models identify distinct imaging and biological pathways that are prognostic of overall survival in glioblastoma	21
EANO - EURACAN - SNO Guidelines on circumscribed astrocytic gliomas, glioneuronal, and neuronal tumors	21
A novel patient stratification strategy to enhance the therapeutic efficacy of dasatinib in glioblastoma	20
Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment	20
Adult immuno-oncology: using past failures to inform the future	20
Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG)	20
Relationship between genetically determined telomere length and glioma risk	20
Phase I trial of convection-enhanced delivery of IL13RA2 and EPHA2 receptor targeted cytotoxins in dogs with spontaneous intracranial gliomas	20
National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States	20
Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: conclusions from the Adult Brain Tumor Consortium’s first workshop on CNS drug delivery	20
BRD4 as a therapeutic target for nonfunctioning and growth hormone pituitary adenoma	19
MEVITEM—a phase I/II trial of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation	19
Delayed referral of pediatric brain tumors during COVID-19 pandemic	19
Phase II study of intrathecal administration of trastuzumab in patients with HER2-positive breast cancer with leptomeningeal metastasis	19
The benefit of early surgery on overall survival in incidental low-grade glioma patients: A multicenter study	19
Extracellular vesicles: The key for precision medicine in glioblastoma	19
Spatial concordance of DNA methylation classification in diffuse glioma	19
Evaluation of mid-term (6-12 months) neurotoxicity in B-cell lymphoma patients treated with CAR T cells: a prospective cohort study	19
Local and systemic therapy of recurrent ependymoma in children and adolescents: short- and long-term results of the E-HIT-REZ 2005 study	19
Characterization of systemic immunosuppression by IDH mutant glioma small extracellular vesicles	19
Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study	19
The histology of brain tumors for 67 331 children and 671 085 adults diagnosed in 60 countries during 2000-2014: a global, population-based study (CONCORD-3)	19
Long-term natural history and patterns of sporadic vestibular schwannoma growth: A multi-institutional volumetric analysis of 952 patients	19
Invasive growth associated with cold-inducible RNA-binding protein expression drives recurrence of surgically resected brain metastases	18
A population study of clinical trial accrual for women and minorities in neuro-oncology following the NIH Revitalization Act	18
Real-time evaluation of glioblastoma growth in patient-specific zebrafish xenografts	18
Adult diffuse glioma GWAS by molecular subtype identifies variants inD2HGDHandFAM20C	18
Disease course of neurofibromatosis type 2: a 30-year follow-up study of 353 patients seen at a single institution	18
NEO100 enables brain delivery of blood‒brain barrier impermeable therapeutics	18
Dysfunctional dendritic cells limit antigen-specific T cell response in glioma	18
HER2 antibody-drug conjugate controls growth of breast cancer brain metastases in hematogenous xenograft models, with heterogeneous blood–tumor barrier penetration unlinked to a passive marker	18
Inhibiting protein phosphatase 2A increases the antitumor effect of protein arginine methyltransferase 5 inhibition in models of glioblastoma	18
ATRX loss promotes immunosuppressive mechanisms in IDH1 mutant glioma	17
Clinical significance and molecular annotation of cellular morphometric subtypes in lower-grade gliomas discovered by machine learning	17
The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas	17
Decitabine increases neoantigen and cancer testis antigen expression to enhance T-cell–mediated toxicity against glioblastoma	17
T lymphocytes as dynamic regulators of glioma pathobiology	17
Value of dynamic contrast perfusion MRI to predict early response to bevacizumab in newly diagnosed glioblastoma: results from ACRIN 6686 multicenter trial	17
Executive summary from American Radium Society’s appropriate use criteria on neurocognition after stereotactic radiosurgery for multiple brain metastases	17
Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort	16
RNA sequence analysis reveals ITGAL/CD11A as a stromal regulator of murine low-grade glioma growth	16
Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma	16
EEG findings in CAR T-cell-associated neurotoxicity: Clinical and radiological correlations	16
Development and validation of a deep-learning model for detecting brain metastases on 3D post-contrast MRI: a multi-center multi-reader evaluation study	16
Development of a gene expression–based prognostic signature for IDH wild-type glioblastoma	16
12p gain is predominantly observed in non-germinomatous germ cell tumors and identifies an unfavorable subgroup of central nervous system germ cell tumors	16
5-Azacitidine in patients with IDH1/2-mutant recurrent glioma	16
Conditional reprogramming culture conditions facilitate growth of lower-grade glioma models	16
Long-term clinically relevant rodent model of methotrexate-induced cognitive impairment	16
Protein sumoylation with SUMO1 promoted by Pin1 in glioma stem cells augments glioblastoma malignancy	16
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions	16
Artificial intelligence (AI)-based decision support improves reproducibility of tumor response assessment in neuro-oncology: An international multi-reader study	16
BET inhibitors repress expression of interferon-stimulated genes and synergize with HDAC inhibitors in glioblastoma	16
Reimagining pilocytic astrocytomas in the context of pediatric low-grade gliomas	16
Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial	16
Heterogeneity and excitability of BRAF V600E-induced tumors is determined by Akt/mTOR-signaling state and Trp53-loss	16
Telomerase as a therapeutic target in glioblastoma	15
Metabolic imaging detects elevated glucose flux through the pentose phosphate pathway associated with TERT expression in low-grade gliomas	15
European genetic ancestry associated with risk of childhood ependymoma	15
Intellectual changes after radiation for children with brain tumors: which brain structures are most important?	15
Sirtuin activation targets IDH-mutant tumors	15
Reactor-based boron neutron capture therapy for 44 cases of recurrent and refractory high-grade meningiomas with long-term follow-up	15
What is the burden of proof for tumor mutational burden in gliomas?	15
Hypermitotic meningiomas harbor DNA methylation subgroups with distinct biological and clinical features	15